{"owner": "ArrayExpress Uploader", "pop_total": 0, "id": 3877, "factors": [{"GSM627985": {"TREATMENT": "DMSO vehicle", "TREATMENT DURATION": "not specified"}}, {"GSM627985": {"TREATMENT": "DMSO vehicle", "TREATMENT DURATION": "not specified"}}, {"GSM627985": {"TREATMENT": "DMSO vehicle", "TREATMENT DURATION": "not specified"}}, {"GSM627988": {"TREATMENT": "PPAR\u03b1 agonist GW7647", "TREATMENT DURATION": "6 hr"}}, {"GSM627988": {"TREATMENT": "PPAR\u03b1 agonist GW7647", "TREATMENT DURATION": "6 hr"}}, {"GSM627988": {"TREATMENT": "PPAR\u03b1 agonist GW7647", "TREATMENT DURATION": "6 hr"}}, {"GSM62799": {"TREATMENT": "PPAR\u03b1 agonist GW7647", "TREATMENT DURATION": "24 hr"}}, {"GSM62799": {"TREATMENT": "PPAR\u03b1 agonist GW7647", "TREATMENT DURATION": "24 hr"}}, {"GSM62799": {"TREATMENT": "PPAR\u03b1 agonist GW7647", "TREATMENT DURATION": "24 hr"}}], "ownerprofile_id": "arrayexpress_sid", "platform": 4, "summary_wrapped": "The transcription factor Peroxisome Proliferator-Activated Receptor \u03b1 (PPAR\u03b1) is an important regulator of hepatic lipid metabolism....", "pubmed_id": 20110263, "geo_gse_id": "E-GEOD-25547", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 2, "sample_count": 9, "tags": ["glutamine", "hepatoma", "lipid", "liver", "peroxisome", "serum"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "profiling-of-promoter-occupancy-by-ppar-in-human-h", "geo_id_plat": "E-GEOD-25547_A-AFFY-44", "name": "Profiling of promoter occupancy by PPAR\u03b1 in human hepatoma cells via ChIP-chip analysis", "created": "Sep.15, 2014", "summary": "The transcription factor Peroxisome Proliferator-Activated Receptor \u03b1 (PPAR\u03b1) is an important regulator of hepatic lipid metabolism. While PPAR\u03b1 is known to activate transcription of numerous genes, no comprehensive picture of PPAR\u03b1 binding to endogenous genes has yet been reported. To fill this gap, we performed ChIP-chip in combination with transcriptional profiling on HepG2 human hepatoma cells treated with the PPAR\u03b1 agonist GW7647. We found that GW7647 increased PPAR\u03b1 binding to 4220 binding regions. GW7647-induced binding regions showed a bias around the transcription start site and most contained a predicted PPAR binding motif. Several genes known to be regulated by PPAR\u03b1, such as ACOX1, SULT2A1, ACADL, CD36, IGFBP1 and G0S2, showed GW7647-induced PPAR\u03b1 binding to their promoter. A GW7647-induced PPAR\u03b1-binding region was also assigned to SREBP-targets HMGCS1, HMGCR, FDFT1, SC4MOL, and LPIN1, expression of which was induced by GW7647, suggesting cross-talk between PPAR\u03b1 and SREBP signaling. Our data furthermore demonstrate interaction between PPAR\u03b1 and STAT transcription factors in PPAR\u03b1-mediated transcriptional repression, and suggest interaction between PPAR\u03b1 and TBP and C/EBP\u03b1 in PPAR\u03b1-mediated transcriptional activation. Overall, our analysis leads to important new insights into the mechanisms and impact of transcriptional regulation by PPAR\u03b1 in human liver and highlight the importance of cross-talk with other transcription factors. HepG2 cells were grown in phenol red-free Dulbecco\u2019s modified medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 0.1 mg/ml streptomycin and 100 U/ml penicillin. Cells were split the day before experiments. Cells were kept at 37 \u00b0C and 5% CO2. The following day, cells were treated with either 100 nM of the PPAR\u03b1 agonist GW7647 or control vehicle (DMSO). Cells used for gene expression analysis were harvested after 6 h or 24 h of GW7647 treatment.  This submission represents the gene expression component of the study.", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-25547", "species": "human", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-25547/samples/"}